Tak­ing Stock

The Economic Times - - Smart -

Pi­ra­mal En­ter­prises GSK Pharma Bio­con S&P BSE Health­care While most pharma com­pa­nies have turned risky on ac­count of reg­u­la­tory clamps, in­vestors have switched to com­pa­nies with healthy pipe­line and strong track record with­FDA.GSKPhar­maseemed­tobe the pre­ferred choice as a de­fen­sive stock. That prob­a­bly ex­plains why de­spite most an­a­lysts hav­ing a bear­ish view of the com­pany’s prospects, the stock emerged to be the top gainer in the sec­toral in­dex year-to-date.

On the other hand, Bio­con has been pre­ferred for its promis­ing prospects on ac­count of its biosim­i­lars port­fo­lio, com­mis­sion­ing of new fa­cil­ity in Malaysia, and list­ing of its sub­sidi- April 28, 2016 ary Syn­gene. A good Q4 show pushed the stock to a new high on Tues­day.

Pi­ra­mal En­ter­prises, with a mot­ley pres­ence in health­care, fi­nan­cial ser­vices and in­for­ma­tion man­age­ment, has been pre­ferred for its high prof­itabil­ity and track record of ef­fi­cient in­vest­ments. Last week, the com­pany made in­vest­ments in two ce­ment com­pa­nies af­ter an ear­lier in­vest­ment in so­lar busi­ness – spark­ing fresh buy­ing in­ter­est in the stock.

Bio­con and Pi­ra­mal, with high pos­si­bil­ity of con­tin­u­ing good per­for­mance, are likely to re­tain in­ter­est even af­ter the reg­u­la­tory risks for other pharma com­pa­nies sub­side.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.